Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ERN, CCA

Braskem posts Recurring EBITDA of US$211 million in the quarter, up 13% from 3Q23


SÃO PAULO, March 19, 2024 /PRNewswire/ -- BRASKEM S.A. (B3: BRKM3, BRKM5 and BRKM6; NYSE: BAK; LATIBEX: XBRK) the largest resin producer in the Americas and the world's leading biopolymers producer, presents its 4Q23 Earnings Release.

4Q23 HIGHLIGHTS 

CONSOLIDATED

The full earnings release is available on the Company's IR website: www.braskem-ri.com.br/en

Braskem will host conference calls to discuss its Results Tuesday, March 19 at 11:00 a.m. US ET.

Additional information may be obtained from the Investor Relations Department at +55 11 3576-9531 or [email protected].

 

SOURCE Braskem S.A.


These press releases may also interest you

at 07:05
Diligent, a leading GRC SaaS company, today announced a first-of-its-kind Enterprise Risk Management (ERM) dashboard powered by industry-leading market data from Moody's , the leading source of relevant insights on exponential risk. The dashboard...

at 07:05
908 Devices Inc. , a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences. 2024 Leerink Partners Healthcare Crossroads Conference,...

at 07:05
Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference...

at 07:05
D-Wave Quantum Inc. ("D-Wave"), a leader in quantum computing systems, software, and services, today announced it is participating in the upcoming Reuters Supply Chain USA 2024 conference, reflecting the company's focus on addressing optimization...

at 07:05
Blackstone today announced the launch of the Blackstone Life Sciences ("Blackstone") portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. Uniquity Bio is emerging from stealth with an FDA...

at 07:05
Rondo Therapeutics, a biopharmaceutical company pioneering next-generation bispecific antibodies, announces oral presentations at both Protein & Antibody Engineering Summit (PEGS) and Antibody Engineering & Therapeutics (AET) EU. Rondo Therapeutics...



News published on and distributed by: